دورية أكاديمية
أعرض في EDS

Pretreatment neutrophil-lymphocyte ratio: an independent predictor of survival in patients with hepatocellular carcinoma.

التفاصيل البيبلوغرافية
العنوان: Pretreatment neutrophil-lymphocyte ratio: an independent predictor of survival in patients with hepatocellular carcinoma.
المؤلفون: Gao F; From the Center of Integrative Medicine (FG, XL, MG, XY, HL, YL, XW); and Statistics Room (GW), Beijing Ditan Hospital, Capital Medical University, Beijing, China., Li X, Geng M, Ye X, Liu H, Liu Y, Wan G, Wang X
المصدر: Medicine [Medicine (Baltimore)] 2015 Mar; Vol. 94 (11), pp. e639.
نوع المنشور: Journal Article; Observational Study; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Biomarkers, Tumor/*blood , Carcinoma, Hepatocellular/*immunology , Liver Neoplasms/*immunology, Adult ; Aged ; Carcinoma, Hepatocellular/mortality ; Carcinoma, Hepatocellular/pathology ; China/epidemiology ; Female ; Humans ; Liver/pathology ; Liver Neoplasms/mortality ; Liver Neoplasms/pathology ; Lymphocyte Count ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; Retrospective Studies
مستخلص: The neutrophil-to-lymphocyte ratio (NLR) has been shown to be associated with prognosis in various types of cancer. We evaluated pretreatment NLR as a predictor of poor prognosis in patients with hepatocellular carcinoma (HCC), and we compared the prognostic value of NLR with other prognostic scores.We retrospectively analyzed 825 patients diagnosed with HCC between October 2008 and May 2012. Baseline data, including the NLR and the Child-Pugh class or Model for End-Stage Liver Disease (MELD) score, were recorded before treatment. The relationships between overall survival (OS) and the study variables were assessed using univariate and multivariate analyses and receiver operating characteristic (ROC) curves. The prognostic value of NLR was assessed using a Kaplan-Meier survival analysis and compared with that of the Barcelona-Clinic Liver Cancer (BCLC) and Tumor, Node, Metastasis (TNM) staging.The NLR, γ-glutamyltranspeptidase, α-fetoprotein ≥ 400 ng/mL, tumor number ≥ 3, tumor size ≥ 5 cm, lymph node metastasis, portal vein involvement, and Child-Pugh class were significantly associated with OS. The NLR demonstrated the strongest prognostic value (area under ROC curve = 0.811). An NLR ≥ 2.7 was a significant predictor of poor OS (P < 0.0001), and the survival period of patients with an NLR ≥ 2.7 decreased with more advanced BCLC and TNM stage.Pretreatment NLR is a useful prognostic biomarker in HCC patients. The prognostic value of NLR ≥ 2.7 is superior to that of MELD stage or Child-Pugh class, and correlates with that of BCLC and TNM staging scores.
References: PLoS One. 2014 Mar 07;9(3):e88182. (PMID: 24609114)
J Hepatol. 2012 Oct;57(4):794-802. (PMID: 22634125)
Am J Surg. 2010 Aug;200(2):197-203. (PMID: 20122680)
Semin Liver Dis. 2010 Feb;30(1):61-74. (PMID: 20175034)
PLoS One. 2013;8(3):e58184. (PMID: 23516447)
J Surg Oncol. 2014 Feb;109(2):95-7. (PMID: 24122764)
N Engl J Med. 2011 Sep 22;365(12):1118-27. (PMID: 21992124)
Int J Cancer. 2009 Sep 15;125(6):1298-305. (PMID: 19431213)
CA Cancer J Clin. 2013 Jan;63(1):11-30. (PMID: 23335087)
Eur J Surg Oncol. 2002 Nov;28(7):723-8. (PMID: 12431469)
Ann Surg. 2013 Aug;258(2):301-5. (PMID: 23774313)
J Pathol. 2011 Nov;225(3):438-47. (PMID: 21826665)
Science. 2011 Mar 25;331(6024):1565-70. (PMID: 21436444)
Trends Immunol. 2009 Nov;30(11):522-30. (PMID: 19775938)
Ann Surg Oncol. 2011 Nov;18(12):3362-9. (PMID: 21547702)
World J Surg Oncol. 2010 Jan 06;8:1. (PMID: 20053279)
J Immunol. 2011 Nov 1;187(9):4818-25. (PMID: 21949019)
Ann Surg. 2001 Jul;234(1):63-70. (PMID: 11420484)
Liver Int. 2009 Apr;29(4):478-80. (PMID: 19323777)
Nature. 2002 Dec 19-26;420(6917):860-7. (PMID: 12490959)
Angiogenesis. 2003;6(4):283-7. (PMID: 15166496)
Ann Surg. 2002 Mar;235(3):373-82. (PMID: 11882759)
Br J Cancer. 2012 Sep 4;107(6):988-93. (PMID: 22878374)
Cancer Res. 2000 Jan 1;60(1):184-90. (PMID: 10646872)
Nat Rev Cancer. 2004 Jan;4(1):71-8. (PMID: 14708027)
Hepatology. 2011 Mar;53(3):1020-2. (PMID: 21374666)
المشرفين على المادة: 0 (Biomarkers, Tumor)
تواريخ الأحداث: Date Created: 20150320 Date Completed: 20150525 Latest Revision: 20220311
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC4602488
DOI: 10.1097/MD.0000000000000639
PMID: 25789957
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-5964
DOI:10.1097/MD.0000000000000639